The 15% withholding for dividends has applied to all of the foreign companies I’ve ever owned, which have included companies from about 20 countries on five continents. I’ve never owned shares of a Greek company, however, so it could be that Greece is an exception.
The new Afinitor approval is for benign brain tumors, not brain cancer. It’s a very small indication that won’t move the needle for a company as large as NVS. Regards, Dew
p.s. One thing that will move the needle for NVS is generic Lovenox, which had $292M in 3Q10 sales following the launch on July 23 (#msg-55774996).